Gut bacteria may be a trigger for antiphospholipid syndrome

November 13, 2016, American College of Rheumatology

The gut microbiomes of patients with antiphospholipid syndrome show higher levels of phospholipid-producing bacteria, and this findings point to microbes being a trigger for this life-threatening disease, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington.

Antiphospholipid syndrome (APS) is an autoimmune disease that mostly affects younger women. Antiphospholipid antibodies are present in some cases of and new strokes in people under age 50, as well as a cause of recurrent miscarriages and pregnancy complications for many women.

Pathogens have been associated with transient antiphospholipid antibodies, so researchers at the Kriegel Lab at Yale University School of Medicine in New Haven, Conn., looked for clues for the source of chronic stimulus of these antibodies in the fecal matter of people with APS.

"Transient antiphospholipid antibodies have long been associated with infections, but are not considered disease-related," said Martin A. Kriegel, MD, PhD, Assistant Professor of Immunology and Medicine and the study's lead author. "We hypothesized that commensals (the microbes normally present in one's gut) that chronically colonize us, instead of acute infections that resolve over time, might be the persistent triggers of APS in ."

APS' exact cause is still unknown. Blood thinners, the current treatment option, only target the blood clots that occur at the end phase of disease, said Dr. Kriegel. This study aimed to find earlier triggers for the disease to possibly prevent deadly strokes and miscarriages. "There's still significant mortality associated with this syndrome compared to other rheumatic diseases in which we can largely prevent mortality nowadays. So there is a huge need to better understand and treat this syndrome," he said.

The researchers collected and analyzed 60 stool samples of 22 APS patients, 13 samples of six control subjects with non-autoimmune, thrombophilic states, and 49 samples of 19 healthy donors, each at baseline, four and eight weeks. Peripheral blood mononuclear cells (PBMCs) from the APS patients responded preferentially to β2-glycoprotein I (GPI), a major auto-antigen in APS, compared to the controls. In addition, the fecal microbiomes of APS patients showed a significant decrease in Bilophilia bacteria and an increase in Slackia bacteria. Fifty-nine percent of the APS patients, but none of the controls, were persistently positive for anti-domain I (DI) antibodies. Increased Slackia and decreased Butyricimonas, a genus of bacteria that produces butyrate, were also significantly correlated to anti-DI IgG positivity in the APS patients. Slackia can produce phospholipids, including cardiolipin, one of the target lipids in APS. The researchers speculated that cardiolipin derived from these could promote autoreactivity against the major B-cell epitope in β2GPI.

"The study's findings are early, but suggest that certain gut microbes are enriched across time in APS patients compared to control subjects. Since we performed not only a cross-sectional microbiome study, but sampled our patients at thee monthly time points and tested how much microbes are coated with IgA antibodies from the patients, we believe that the gut microbes we identified as promising candidates should be studied further," said Dr. Kriegel. "These eventually may become biomarkers of disease or even treatment targets, but we're still far away from these goals."

One day, doctors may be able to identify APS biomarkers in patients' fecal microbiomes. Dr. Kriegel's laboratory is currently testing functional links between these microbes and APS.

"The immediate next step is to culture the candidate bacteria that emerged from the study and put them together with immune cells from the patients," he said. "In particular, we would like to test if cardiolipin could be derived from our candidate bacteria and, therefore, be recognized by the patients' immune cells that are known to target these lipids."

Explore further: Malaria drug combo could help prevent pregnancy complications in lupus patients

Related Stories

Malaria drug combo could help prevent pregnancy complications in lupus patients

January 22, 2014
An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new ...

mTORC pathway involved in antiphospholipid sx vasculopathy

July 24, 2014
(HealthDay)—The mammalian target of rapamycin complex (mTORC) pathway seems to be involved in antiphospholipid syndrome-associated vascular lesions, according to a study published in the July 24 issue of the New England ...

Respiratory tract bacterium uncovered as trigger for serious nervous system disease

October 3, 2016
Guillain-Barré syndrome (GBS) is an acute life-threatening disease of the nervous system that leads to sensory disturbances and acute flaccid paralysis. A group of researchers involving the University of Zurich has now shown ...

Gut microbes linked to immunotherapy response in melanoma patients

November 7, 2016
Patients with malignant melanoma - whose disease has spread - are more likely to respond to immunotherapy treatment if they had greater diversity in their gut bacteria, according to new research presented at the National ...

M. pneumoniae infection linked to Guillain-Barre syndrome

August 16, 2016
(HealthDay)—Mycoplasma pneumoniae infection is associated with Guillain-Barré syndrome (GBS), according to a study published online Aug. 4 in the Annals of Neurology.

Gut bacteria tire out T cells

September 15, 2014
Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Medicine ...

Recommended for you

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis

November 20, 2017
Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.

Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy

November 16, 2017
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was ...

Study lists foods for fighting rheumatoid arthritis symptoms and progression

November 8, 2017
A list of food items with proven beneficial effects on the progression and symptoms of rheumatoid arthritis is provided in a new study published today in Frontiers in Nutrition. The authors suggest incorporating these foods ...

Prototype equipment can detect rheumatoid arthritis

September 28, 2017
According to a first clinical study published in the scientific journal Photoacoustics, the University of Twente and various European partners have designed a device that shows the difference between healthy fingers and arthritic ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.